In preclinical data, it is identified that pemetrexed combined with erlotinib could achieve good response than pemetrexed because EGFR-TKI (erlotinib) could enhance the sensitivity of pemetrexed. So we design the trial to investigate curative effect between Pemetrexed/Cisplatin and Pemetrexed/Cisplatin intercalating Gefitinib Treating EGFR Wild NSCLC.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1.Histological or cytological diagnosis of small-cll lung cancer histology
2.18 years or older
3.Eastern Cooperative Oncology Group (ECOG) Performance Status no more than 2
4.Local stage SCLC without distant metastases
5.After 1st-line chemotherapy (EP or IP) at least 4 cycles
6.After radical radiotherapy for primary tumor and lymph node drainage area:including concurrent or sequence chemoradiotherapy
7.CR or PR assessment by RECIST(1.0) before randomized
9.Total bilirubin 1.5 x upper limit of normal (ULN) alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 2.5 x ULN in the absence of liver metastases, or \< 5 x ULN in case of liver metastases
10.Creatinine clearance 60ml/min (calculated according to Cockcroft-gault formula)
You may not be if
1. Mixed non-small cell lung cancer histology
2. Neck and supraclavicular lymph node metastasis
3. Be allergic to temozolomide or intolerable to radiotherapy
